| abstract |
The present invention includes 1-15 amino acid modifications relative to human factor VII or human factor VIIa, wherein the hydrophobic amino acid residue is introduced by substitution at position 34, or has amino acid substitution at position 36, or at positions 10 and Disclosed are Gla domain variants of human factor VII or human factor VIIa having amino acid substitutions at 32 and at least one additional amino acid substitution at positions selected from 74, 77 and 116. |